FBLG: FibroBiologics, Inc. - Summary | Jitta

FibroBiologics, Inc.

NASDAQ:FBLG

Price
$0.93
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (3)
Recent Business Performance (12)
Financial Strength (37)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.21
131.14%
3.05
162.56%
Biotechnology
5.68
37.68%
5.68
37.68%
6.36
42.66%
COMPANY DESCRIPTION
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.